Debevoise Advises Guggenheim Securities and Morgan Stanley & Co. as Financial Advisors to Pfizer in its $11.4 Billion Acquisition of Array Biopharma Inc.

17 June 2019

Debevoise & Plimpton LLP is advising Guggenheim Securities, LLC and Morgan Stanley & Co. LLC as financial advisors to Pfizer Inc. (NYSE: PFE) in connection with Pfizer’s $11.4 billion acquisition of Array BioPharma Inc (NASDAQ: ARRY).

Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm with more than $265 billion in assets under management. Morgan Stanley is a leading global financial services firm providing investment banking, securities, wealth management and investment management services. Pfizer is one of the world’s premier innovative biopharmaceutical companies, applying science and global resources to bring therapies to people that extend and significantly improve their lives. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

The Debevoise team is led by partner Andrew Bab and includes associates Bill Barlow and Sean Foley.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.